Literature DB >> 4647074

Metabolism of 3,4-dihydroxyphenylalanine (L-dopa) in human subjects.

M Goodall, H Alton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4647074     DOI: 10.1016/0006-2952(72)90392-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  7 in total

1.  Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease.

Authors:  A K Granerus; R Jagenburg; A Svanborg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

3.  Urinary catecholamine metabolites (vanylmandelic and homovanillic acids) in the rat after subchronic treatment with sodium nitrate or nitrite.

Authors:  S Laurens; P Fritsch; G de Saint Blanquat
Journal:  Experientia       Date:  1982-04-15

Review 4.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Determination of levodopa by chromatography-based methods in biological samples: a review.

Authors:  Ruiqi Jiang; Jiayu Yang; Shenghui Mei; Zhigang Zhao
Journal:  Anal Sci       Date:  2022-06-17       Impact factor: 1.967

6.  Studies on the sulphation of 3,4-dihydroxyphenylethylamine (dopamine) and related compounds by rat tissues.

Authors:  W N Jenner; P A Rose
Journal:  Biochem J       Date:  1973-09       Impact factor: 3.857

7.  Toward the understanding of the metabolism of levodopa I. DFT investigation of the equilibrium geometries, acid-base properties and levodopa-water complexes.

Authors:  Shabaan A K Elroby; Mohamed S I Makki; Tariq R Sobahi; Rifaat H Hilal
Journal:  Int J Mol Sci       Date:  2012-04-02       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.